J&J Maintains Consumer Business Outlook Despite 'Disappointing' Quarter
You may also be interested in...
J&J Hopes To Continue Appellate Streak Following Whopping $4.69bn Talc Verdict
Counsel for 22 women who blame J&J talcum powders for their ovarian cancer took a new approach in this latest case in St. Louis Circuit Court, arguing that asbestos in the firm’s talc is the culprit, rather than talc itself. J&J is confident in its ability to overturn the verdict, which it characterized as biased and unfounded.
Listerine Sensitivity Tops J&J Innovation Pipeline In '18
Johnson & Johnson will launch a Listerine mouthwash incorporating a class II device to address tooth sensitivity, Chief Technology Officer John Ghaim said during J&J’s Medical Devices & Consumer Analyst Day May 16. The company plans to launch 150 new products globally in 2018, which should help the company achieve sales ahead of the consumer health category.
J&J Consumer Health On Solid Footing With Help From Personal Care Sales
Analysts say firm’s consumer health division is showing signs of a comeback, with worldwide sales up 5.3% to $3.4bn, boosted 3.7% from currency exchange on strong beauty segment sales, driven by increased online marketing, and strengthening OTC drug sales.